

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

### High-sensitivity troponin tests for the early rule out of NSTEMI

#### Stakeholder list

<b>Manufacturers</b> Abbott Laboratories Beckman Coulter UK Ltd BioMérieux Quidel Ireland Ortho Clinical Diagnostics Roche Diagnostics Ltd Siemens Healthineers
<b>Manufacturers of related technologies</b> Thermo Fisher Scientific Randox Laboratories Ltd Radiometer Ltd
<b>Professional groups</b> Association for Clinical Biochemistry and Laboratory Medicine British Cardiovascular Society Innovation Agency Academic Health Science Network Royal College of Physicians Society for Acute Medicine
<b>Patient/carer groups</b>
<b>Research groups</b> King's College London School of Cardiovascular Medicine and Sciences
<b>Associated guideline groups</b>
<b>External Assessment Group</b> Kleijnen Systematic Reviews
<b>Others</b> Department of Health Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency NHS England UK NEQAS Welsh Government

**Definitions:****Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

**External Assessment Group (EAG)**

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).